Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn
The selected candidate can be developed as a monotherapy, combination therapy or both
Read More
The selected candidate can be developed as a monotherapy, combination therapy or both
Read MoreThe company will gain rights to Alpine’s lead molecule, povetacicept, to treat IgA nephropathy
Read MoreThe transaction also includes the sale of Arvinas’ preclinical AR-V7 programme
Read MoreAs part of the deal, Merck will gain access to the start-up’s payload selectivity enhancer technology
Read MoreCardiovascular disease results in an estimated 17.9 million global deaths every year
Read MoreThe deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours
Read MoreSTRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio
Read MoreXTX301 is currently being evaluated in a phase 1 trial in patients with advanced solid tumours
Read MoreThe deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications
Read MoreThe deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease
Read MoreThe deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients
Read MoreThe transaction includes a potential new treatment for metastatic castration-resistant prostate cancer
Read MoreAccount Specialist - Respiratory - Kent & Medway
Market Access Business Manager - Advanced Wound Care - North
Key Account Manager - Urology - East Anglia, Beds & Bucks
Therapy Development Specialist - Greater London & East Anglia